Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$2.39
-4.8%
$2.24
$1.60
$16.55
$177.41M1.111.04 million shs656,911 shs
Nevro Corp. stock logo
NVRO
Nevro
$5.85
+0.1%
$5.84
$3.17
$10.37
$224.32M0.81767,447 shs753,602 shs
Vivos Inc. stock logo
RDGL
Vivos
$0.13
+4.3%
$0.12
$0.06
$0.26
$60.32M1.1954,414 shs493,054 shs
The Beauty Health Company stock logo
SKIN
Beauty Health
$1.61
-6.9%
$1.24
$0.78
$2.59
$201.64M0.881.05 million shs361,625 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-4.78%-9.13%+3.46%-14.18%-83.96%
Nevro Corp. stock logo
NVRO
Nevro
0.00%0.00%0.00%+1.94%-40.41%
Vivos Inc. stock logo
RDGL
Vivos
+4.31%-2.13%+26.67%+10.01%-11.43%
The Beauty Health Company stock logo
SKIN
Beauty Health
-6.94%-7.47%+70.19%0.00%-39.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.2232 of 5 stars
4.60.00.00.02.12.50.6
Nevro Corp. stock logo
NVRO
Nevro
0.2009 of 5 stars
1.00.00.00.00.61.70.6
Vivos Inc. stock logo
RDGL
Vivos
N/AN/AN/AN/AN/AN/AN/AN/A
The Beauty Health Company stock logo
SKIN
Beauty Health
0.3737 of 5 stars
0.80.00.00.02.83.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.50423.01% Upside
Nevro Corp. stock logo
NVRO
Nevro
1.92
Reduce$5.36-8.29% Downside
Vivos Inc. stock logo
RDGL
Vivos
0.00
N/AN/AN/A
The Beauty Health Company stock logo
SKIN
Beauty Health
1.67
Reduce$1.42-12.01% Downside

Current Analyst Ratings Breakdown

Latest RDGL, NVRO, SKIN, and CATX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
5/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
5/5/2025
The Beauty Health Company stock logo
SKIN
Beauty Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$1.50 ➝ $1.25
4/7/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $10.00
3/31/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/27/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.00
3/26/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
3/19/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/17/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
3/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
3/13/2025
The Beauty Health Company stock logo
SKIN
Beauty Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$1.75 ➝ $1.50
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$1.43M124.06N/AN/A$2.67 per share0.90
Nevro Corp. stock logo
NVRO
Nevro
$408.52M0.55N/AN/A$8.10 per share0.72
Vivos Inc. stock logo
RDGL
Vivos
$20K3,015.85N/AN/A($0.02) per share-6.65
The Beauty Health Company stock logo
SKIN
Beauty Health
$322.47M0.63N/AN/A$0.48 per share3.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)
Vivos Inc. stock logo
RDGL
Vivos
-$2.89M-$0.01N/AN/AN/AN/A-197.34%8/11/2025 (Estimated)
The Beauty Health Company stock logo
SKIN
Beauty Health
-$100.12M-$0.41N/AN/AN/A-8.11%-44.83%-3.54%N/A

Latest RDGL, NVRO, SKIN, and CATX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
The Beauty Health Company stock logo
SKIN
Beauty Health
-$0.13-$0.08+$0.05-$0.08$63.88 million$69.60 million
3/12/2025Q4 2024
The Beauty Health Company stock logo
SKIN
Beauty Health
-$0.10-$0.08+$0.02-$0.08$78.02 million$83.50 million
3/4/2025Q4 2024
Nevro Corp. stock logo
NVRO
Nevro
-$0.79-$0.64+$0.15-$1.41$102.61 million$105.55 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A
Vivos Inc. stock logo
RDGL
Vivos
N/AN/AN/AN/AN/A
The Beauty Health Company stock logo
SKIN
Beauty Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
Nevro Corp. stock logo
NVRO
Nevro
0.67
5.02
3.76
Vivos Inc. stock logo
RDGL
Vivos
N/A
25.48
25.48
The Beauty Health Company stock logo
SKIN
Beauty Health
9.23
6.56
5.57

Institutional Ownership

CompanyInstitutional Ownership
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
Nevro Corp. stock logo
NVRO
Nevro
95.52%
Vivos Inc. stock logo
RDGL
Vivos
N/A
The Beauty Health Company stock logo
SKIN
Beauty Health
93.26%

Insider Ownership

CompanyInsider Ownership
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.72%
Nevro Corp. stock logo
NVRO
Nevro
3.20%
Vivos Inc. stock logo
RDGL
Vivos
18.50%
The Beauty Health Company stock logo
SKIN
Beauty Health
41.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.23 million65.21 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,09038.37 million36.27 millionOptionable
Vivos Inc. stock logo
RDGL
Vivos
1453.51 million369.81 millionNot Optionable
The Beauty Health Company stock logo
SKIN
Beauty Health
1,030125.25 million73.23 millionOptionable

Recent News About These Companies

You Are Doing Too Much for Your Skin Barrier

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$2.39 -0.12 (-4.78%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.44 +0.05 (+2.30%)
As of 05/23/2025 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Nevro stock logo

Nevro NYSE:NVRO

$5.85 +0.01 (+0.10%)
Closing price 04/2/2025
Extended Trading
$5.85 0.00 (0.00%)
As of 04/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Vivos stock logo

Vivos OTCMKTS:RDGL

$0.13 +0.01 (+4.31%)
As of 05/23/2025 03:52 PM Eastern

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

Beauty Health stock logo

Beauty Health NASDAQ:SKIN

$1.61 -0.12 (-6.94%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.66 +0.05 (+3.42%)
As of 05/23/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.